Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Clinical Psychiatry

• Publication date

  2009-08-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.4088/JCP.08m04548PMID 19689920
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.

  2007cited by this paper
• Overweight and obesity affect treatment response in major depression.

  2007cited by this paper
• Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine

  2007cited by this paper
• BMI, sex, and antidepressant response.

  2007cited by this paper
• Duloxetine in the prevention of relapse of major depressive disorder

  2006cited by this paper
• Antidepressant discontinuation syndrome.

  2006cited by this paper
• Prevention of relapse in generalized anxiety disorder by escitalopram treatment.

  2006cited by this paper
• Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.

  2006cited by this paper
• Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.

  2006cited by this paper
• Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists.

  2004cited by this paper
• Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.

  2004cited by this paper
• Escitalopram continuation treatment prevents relapse of depressive episodes.

  2004cited by this paper
• Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

  2004cited by this paper
• Placebo-Controlled Continuation Treatment with Mirtazapine: Acute Pattern of Response Predicts Relapse

  2004cited by this paper
• New selective ligands of human cloned melatonin MT1 and MT2 receptors

  2003cited by this paper
• The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

  2003cited by this paper
• Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review.

  2003cited by this paper
• Tolerability and adherence issues in antidepressant therapy.

  2003cited by this paper
• Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression.

  2002cited by this paper
• Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

  2002cited by this paper
• Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients.

  2001cited by this paper
• Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study.

  2001cited by this paper
• Tolerability and patient compliance.

  1999cited by this paper
• Redefining antidepressant efficacy toward long-term recovery.

  1999cited by this paper
• Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment.

  1998cited by this paper
• Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments.

  1998cited by this paper
• Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo.

  1998cited by this paper
• The measurement of disability

  1996cited by this paper
• Novel naphthalenic ligands with high affinity for the melatonin receptor.

  1992cited by this paper
• Methodologic issues in maintenance therapy clinical trials.

  1991cited by this paper
• Continuation drug therapy for major depressive episodes: how long should it be maintained?

  1986cited by this paper
• The Hospital Anxiety and Depression Scale

  1983cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Comparison of antidepressant deprescribing strategies in individuals with clinically remitted depression: a systematic review and network meta-analysis.

  2026cites this paper
• Testing the internal validity of the maintenance/discontinuation study design for antidepressant medications in depression using simulations

  2025cites this paper
• Evidence on antidepressant withdrawal: an appraisal and reanalysis of a recent systematic review

  2025influential citation
• Strategies for antidepressant medications in the maintenance phase: A systematic review and network Meta-analysis.

  2025cites this paper
• Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension study

  2024cites this paper
• Melatonin and its physiological and therapeutic effects: A review

  2024cites this paper
• When to stop medication in unipolar depression: A systematic review and a meta-analysis of randomized controlled trials.

  2023cites this paper
• Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders

  2023cites this paper
• Efficacy and safety of agomelatine versus SSRIs/SNRIs for post-stroke depression: a systematic review and meta-analysis of randomized controlled trials

  2023cites this paper
• Efficacy and safety of agomelatine in the treatment of patients with depressive disorder: A meta-analysis

  2023cites this paper
• Agomelatine in the treatment of anhedonia, somatic symptoms, and sexual dysfunction in major depressive disorder

  2023cites this paper
• Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis

  2022cites this paper
• The efficacy and safety of agomelatine, sertraline, and escitalopram for senile post-stroke depression: A randomized double-blind placebo-controlled trial.

  2021cites this paper
• Agomelatine: Profile and applications to depression

  2021cites this paper
• Acupuncture Treatment Reduced the Risk of Coronary Heart Disease in Patients with Depression: A Propensity-Score Matched Cohort Study

  2021cites this paper
• Antidepressants: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy

  2021cites this paper
• Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults.

  2021cites this paper
• Prophylactic effects or withdrawal reactions? An analysis of time-to-event data from antidepressant relapse prevention trials submitted to the FDA

  2021cites this paper
• NDT_A_315572 2315..2325

  2021cites this paper
• Pharmacological Treatment of Generalized Anxiety Disorder (GAD)

  2020cites this paper
• Drugs to Treat Anxiety and Insomnia

  2020cites this paper
• Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications

  2020cites this paper
• Withdrawal effects confounding in clinical trials: another sign of a needed paradigm shift in psychopharmacology research

  2020cites this paper
• Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed.

  2020cites this paper
• Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis

  2020cites this paper
• The preclinical discovery and development of agomelatine for the treatment of depression

  2020cites this paper
• Antidepressant Withdrawal and Rebound Phenomena.

  2019cites this paper
• Agomelatine for depression: expanding the horizons?

  2019cites this paper
• Überfällige ärztliche Hilfen

  2019cites this paper
• Agomelatine Effectiveness, Tolerability, and Impact on Anhedonia in Major Depression: A Pooled Analysis

  2019cites this paper
• Melatonin and agomelatine for preventing seasonal affective disorder.

  2019cites this paper
• Molecular basis for the association between depression and circadian rhythm

  2019cites this paper
• Spike-Wave Discharges and Sleep-Wake States during Circadian Desynchronization: No Effects of Agomelatine upon Re-Entrainment.

  2019cites this paper
• Depression in primary care: part 2—management

  2019cites this paper
• Application of Item Response Theory to Model Disease Progression and Agomelatine Effect in Patients with Major Depressive Disorder

  2019cites this paper
• Withdrawal Confounding in Randomized Controlled Trials of Antipsychotic, Antidepressant, and Stimulant Drugs, 2000–2017

  2019cites this paper
• Circadian gene expression of tryptophan hydroxylase 2 in the dorsal and median raphe nuclei is altered by dysregulated glucocorticoid rhythms

  2019cites this paper
• An electrophysiological investigation of the extrinsic modulation of ventral pallidum neurons by dopamine and serotonin

  2018cites this paper
• Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial

  2018cites this paper
• [Switching and stopping antidepressants].

  2018cites this paper
• Anxiolytic properties of compounds that counteract oxidative stress, neuroinflammation, and glutamatergic dysfunction: a review

  2018cites this paper
• Treatment of anxiety disorders

  2017cites this paper
• Pooled Analysis of Four Non-Interventional Studies: Effectiveness and Tolerability of the Antidepressant Agomelatine in Daily Practice

  2017cites this paper
• Bioequivalence and Pharmacokinetic Profiles of Agomelatine 25-mg Tablets in Healthy Chinese Subjects: A Four-Way Replicate Crossover Study Demonstrating High Intra- and Inter-Individual Variations.

  2017cites this paper
• Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom.

  2017cites this paper
• Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: results of the national multicenter observational study PULSE

  2017cites this paper
• Melatonin produces a rapid onset and prolonged efficacy in reducing depression-like behaviors in adult rats exposed to chronic unpredictable mild stress.

  2017cites this paper
• Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland

  2017cites this paper
• CHARACTERIZATION OF AGOMELATINE-INDUCED LIVER ENZYME INCREASE : FREQUENCY AND RISK FACTORS DERTERMINED FROM A POOLED ANALYSIS OF 7 , 605 TREATED PATIENTS

  2017cites this paper
• New targets for rapid antidepressant action.

  2017cites this paper
• Recognition and management of antidepressant discontinuation syndrome.

  2017cites this paper
• Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: Randomised double-blind placebo-controlled trial

  2016cites this paper
• Caffeine augments the antidepressant-like activity of mianserin and agomelatine in forced swim and tail suspension tests in mice

  2016cites this paper
• Suicides and Suicide Attempts during Long-Term Treatment with Antidepressants: A Meta-Analysis of 29 Placebo-Controlled Studies Including 6,934 Patients with Major Depressive Disorder

  2016cites this paper
• Augmentation of antidepressant effects of venlafaxine by agomelatine in mice are independent of kynurenine pathway.

  2016cites this paper
• Antidépresseurs : aspects thérapeutiques

  2016cites this paper
• Agomelatine versus Sertraline: An Observational, Open-labeled and 12 Weeks Follow-up Study on Efficacy and Tolerability

  2016cites this paper
• Opioid system mediated anti-nociceptive effect of agomelatine in mice.

  2016cites this paper
• Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants

  2016cites this paper
• Melatonergic Antidepressant Agomelatine and Its Efficacy in Depressive Disorders

  2016cites this paper
• Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients

  2016cites this paper
• Agomelatine, Melatonin and Depression

  2016cites this paper
• Behavioral, neuroendocrine and neurochemical studies on agomelatine in social isolation reared rats

  2015cites this paper
• Profile of agomelatine and its potential in the treatment of generalized anxiety disorder

  2015cites this paper
• Profile of agomelatine and its potential in the treatment of generalized anxiety disorder

  2015cites this paper
• A systematic review of agomelatine-induced liver injury

  2015cites this paper
• Profile of agomelatine and its potential in the treatment of generalized anxiety disorder

  2015cites this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 2: Maintenance Treatment of Major Depressive Disorder-Update 2015

  2015cites this paper
• Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression

  2015cites this paper
• Combination of agomelatine and bupropion for treatment-resistant depression: results from a chart review study including a matched control group

  2015cites this paper
• COMPARATIVE REVIEW OF A NOVEL MELATONERGIC ANTIDEPRESSANT DRUG- AGOMELATINE

  2015cites this paper
• Agomelatine

  2015cites this paper
• Melatonin and agomelatine for preventing seasonal affective disorder.

  2015cites this paper
• The use of agomelatine in OCD: effects on the motivational aspects and dysregulated circadian rhythms

  2015cites this paper
• Light-At-Night and Mood: Examining The Role Of Sex In C57Bl/6 Mice

  2015cites this paper
• Agomelatin – Update aktueller Daten 2015

  2015cites this paper
• Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials

  2015cites this paper
• Emerging antidepressants to treat major depressive disorder.

  2014cites this paper
• Agomelatine: A Neuroprotective Agent with Clinical Utility beyond Depression and Anxiety

  2014cites this paper
• Agomelatine: 새로운 기전의 항우울제

  2014cites this paper
• Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies

  2014cites this paper
• Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks

  2014cites this paper
• agomelatine in the treatment of depressive disorders in clinical practice: multicenter observational chrONOs study

  2014cites this paper
• Efficacy and tolerability of agomelatine in the treatment of depression

  2014cites this paper
• Melatonin in Mood Disorders and Agomelatine’s Antidepressant Efficacy

  2014cites this paper
• The mechanism, efficacy, and tolerability profile of agomelatine

  2014cites this paper
• Comparative Assessment of the Efficacy of Valdoxane (agomelatine) in Recurrent Depression and Bipolar Affective Disorder

  2014cites this paper
• Agomelatine in Depressive Disorders

  2014cites this paper
• Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

  2014cites this paper
• Chapter 2 - Antidepressant drugs

  2014cites this paper
• Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies

  2014cites this paper
• Circadian arrhythmia dysregulates emotional behaviors in aged Siberian hamsters.

  2014cites this paper
• Agomelatine Is Effective in Reducing Insomnia in Abstinent Alcohol-Dependent Patients

  2014cites this paper
• Melatonergic Drugs as Therapeutic Agents for Insomnia and Depressive Disorders

  2014cites this paper
• [Agomelatine: fulminant liver failure in a patient with fatty liver].

  2014cites this paper
• Efficacy and tolerability of agomelatine in the treatment of depression

  2014influential citation
• Agomelatine in the treatment of depressive disorders in clinical practice: multicenter observational CHRONOS study

  2014cites this paper
• Melatonin synergizes with citalopram to induce antidepressant‐like behavior and to promote hippocampal neurogenesis in adult mice

  2014cites this paper
• Melatonergic Antidepressant Agomelatine in Depressive and Anxiety Disorders

  2014cites this paper
• Agomelatine: The Novel Antidepressant

  2014cites this paper